Roche Holding AG, a major Swiss pharmaceutical company, has recently reported about a 4% sales increase in 2012. The sales boosted up to 4.5.5 billion francs.
The company’s experts expects the positive tendency to continue in 2013.
The company’s income per share increased by 10% up to 13.62 Swiss francs per share.
The free money flow of Roche Holding AG increased by 10% up to 15,4 billion Swiss francs during the reporting period.
Mass media report that the company’s board of directors offered to boost the dividend payments for 2012 by 8% up to 7.35 francs per share.
For reference sake, Roche Holding AG specializes in manufacturing biotechnological medicine.
The chart below, courtesy of , reflects the current state of affairs in the market of RHHBY:
